Signal from the log
HexemBio
15,5 M$ · Early stage · United States
HexemBio recrée en laboratoire l'environnement du sac vitellin humain pour rajeunir des cellules souches du sang vieillissantes. Premier usage visé, améliorer les greffes de moelle osseuse, avec un essai chez l'homme annoncé pour 2027. La désignation de médicament orphelin a été obtenue en juillet 2025.
Verified
Announced on , logged by the watch of 15 September 2026.
- Operation
- Funding round
- Announced amount
- 15,5 M$
- Stage
- Early stage
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Draper Associates , with Happiness Capital
Provenance
Source longevity
Logged on 15 September 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.